An investigation into the mechanism of capsaicin-induced oedema in rabbit skin

Br J Pharmacol. 1995 Feb;114(3):570-7. doi: 10.1111/j.1476-5381.1995.tb17177.x.

Abstract

1. Oedema formation induced by intradermal capsaicin has been studied in rabbit skin. The effect of the anti-inflammatory steroid dexamethasone and also of a range of known inhibitors of oedema formation have been investigated in order to elucidate mechanisms involved in capsaicin-induced oedema formation. 2. Oedema formation, in response to intradermally-injected test agents, was measured by the local extravascular accumulation of intravenously injected 125I-labelled albumin. In separate experiments skin blood flow was assessed by the clearance of intradermally-injected 133xenon. 3. Oedema formation induced by intradermal histamine (3 nmol) and bradykinin (1 nmol), when in the presence of vasodilator doses of calcitonin gene-related peptide (CGRP) (3 pmol) or prostaglandin E1, (PGE1) (10 pmol), was significantly inhibited (P < 0.01) in rabbits pretreated with intravenous dexamethasone (3 mg kg-1, -4 h). In contrast dexamethasone had no effect on capsaicin (3 mumol)-induced oedema formation or, on capsaicin (30-100 nmol)-induced blood flow. 4. Oedema formation observed in response to intradermal capsaicin (3 mumol) was significantly inhibited (P < 0.01) when the selective capsaicin antagonist, ruthenium red (3 nmol) was co-injected. This suggests that the mechanism of capsaicin-induced oedema involves activation of sensory nerves. However, oedema was not inhibited when capsaicin was co-injected with the neurokinin NK1 receptor antagonist, RP67580 (10 nmol), the NK2 antagonist SR48960 (10 nmol) or the CGRP antagonist CGRP8-37 (300 pmol). 5. Oedema formation induced by capsaicin was not inhibited when co-injected with the histamine HI receptor antagonist, mepyramine (3 nmol), the PAF antagonist, WEB 2086 (100 nmol), the bradykinin B2 receptor antagonist, Hoel4O (1 nmol), or the cyclo-oxygenase inhibitor, indomethacin (10 nmol),suggesting that these mediators do not play a major role in the capsaicin-induced response.6. Histological analysis of capsaicin-treated skin sites revealed undamaged, intact microvessels and lack of haemorrhage. Further, co-injection of capsaicin with the hydrogen peroxide remover, catalase(2,200 u), had no effect on oedema formation. This suggests that capsaicin does not induce oedema formation secondary to free radical-induced damage.7. These results indicate that capsaicin-induced oedema in rabbit skin involves activation of sensory nerves. However, the oedema is not inhibited by pretreatment with the anti-inflammatory steroid,dexamethasone. Further the mechanisms which lead to the oedema formation observed after intradermal capsaicin remain unknown.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alprostadil / administration & dosage
  • Alprostadil / pharmacology
  • Alprostadil / therapeutic use
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Benzamides / administration & dosage
  • Benzamides / pharmacology
  • Benzamides / therapeutic use
  • Bradykinin / administration & dosage
  • Bradykinin / toxicity
  • Calcitonin Gene-Related Peptide / administration & dosage
  • Calcitonin Gene-Related Peptide / antagonists & inhibitors
  • Calcitonin Gene-Related Peptide / pharmacology
  • Calcitonin Gene-Related Peptide / therapeutic use
  • Capillary Permeability / drug effects
  • Capsaicin / administration & dosage
  • Capsaicin / toxicity*
  • Catalase / administration & dosage
  • Catalase / pharmacology
  • Catalase / therapeutic use
  • Dexamethasone / administration & dosage
  • Dexamethasone / pharmacology
  • Dexamethasone / therapeutic use
  • Drug Interactions
  • Edema / chemically induced*
  • Edema / drug therapy
  • Edema / physiopathology
  • Histamine / administration & dosage
  • Histamine / toxicity
  • Indoles / administration & dosage
  • Indoles / pharmacology
  • Indoles / therapeutic use
  • Indomethacin / administration & dosage
  • Indomethacin / pharmacology
  • Indomethacin / therapeutic use
  • Injections, Intradermal
  • Injections, Intravenous
  • Isoindoles
  • Male
  • Piperidines / administration & dosage
  • Piperidines / pharmacology
  • Piperidines / therapeutic use
  • Rabbits
  • Regional Blood Flow / drug effects
  • Ruthenium Red / administration & dosage
  • Ruthenium Red / pharmacology
  • Ruthenium Red / therapeutic use
  • Skin / blood supply
  • Skin / drug effects*
  • Skin / pathology
  • Substance P / antagonists & inhibitors
  • Vasodilator Agents / administration & dosage
  • Vasodilator Agents / pharmacology
  • Vasodilator Agents / therapeutic use

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Benzamides
  • Indoles
  • Isoindoles
  • Piperidines
  • Vasodilator Agents
  • Ruthenium Red
  • 7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one
  • Substance P
  • SR 48968
  • Dexamethasone
  • Histamine
  • Catalase
  • Alprostadil
  • Calcitonin Gene-Related Peptide
  • Capsaicin
  • Bradykinin
  • Indomethacin